
Rozalina G McCoy MD MS (She/Her)
Diabetes
Associate Professor of Medicine
Join to View Full Profile
670 W Baltimore StBaltimore, MD 21201
Phone+1 410-706-7167
Dr. McCoy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Endocrinology, Diabetes, and Metabolism, 2012 - 2015
- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2009 - 2012
- Johns Hopkins University School of MedicineClass of 2009
Certifications & Licensure
- MD State Medical License 2023 - 2025
- MN State Medical License 2010 - 2023
- WI State Medical License 2020 - 2023
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Clinical Trials
- Community Paramedicine Program to Improve Diabetes Care Quality, Equity, and Outcomes Start of enrollment: 2020 Jul 13
Publications & Presentations
PubMed
- Reimagining Resilience in Aging: Leveraging AI/ML, Big Data Analytics, and Systems Innovation.Jie Chen, Teagan K Maguire, Rozalina G McCoy, Stephen Thomas, Charles F Reynolds 3rd
The American Journal of Geriatric Psychiatry. 2025-09-01 - Heterogeneity of Cardiovascular Effects of Second-Line Glucose-Lowering Therapies in Adults With Type 2 Diabetes Across the Range of Moderate Baseline Cardiovascular R...Yihong Deng, Eric C Polley, Jeph Herrin, Kavya S Swarna, David M Kent
Journal of the American Heart Association. 2025-08-05 - Fill Patterns of Glucose-Lowering Drugs with Cardiovascular and Kidney Benefits in the Rural and Urban United States, 2012-2021.Kyle Steiger, Kavya Sindhu Swarna, Jeph Herrin, Rozalina G McCoy
Journal of General Internal Medicine. 2025-08-04
Press Mentions
- Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV RisksAugust 1st, 2025
- Cardiovascular Risks Resurface Old Concerns About Sulfonylureas for T2DJuly 24th, 2025
- Standards of Care in Diabetes—2025 Brings Updates to PracticeJune 23rd, 2025
- Join now to see all
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: